home / stock / cyad / cyad news

CYAD News and Press, Celyad SA From 11/02/20

Stock Information
Company Name: Celyad SA
Stock Symbol: CYAD
Market: NASDAQ
Menu
CYAD CYAD Quote CYAD Short CYAD News CYAD Articles CYAD Message Board
Get CYAD Alerts

News, Short Squeeze, Breakout and More Instantly...
CYAD - Celyad Oncology Announces November 2020 Investor Conference Schedule

MONT-SAINT-GUIBERT, Belgium, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company...
CYAD - Celyad to evaluate CYAD-101/KEYTRUDA combo in colorectal cancer

Celyad Oncology ([[CYAD]]) announces a clinical trial collaboration with Merck, wherein Celyad will conduct a Phase 1b KEYNOTE-B79 trial, evaluating its CYAD-101, following FOLFIRI (combination of 5-fluorouracil, leucovorin and irinotecan) preconditioning chemotherapy, with latter's KEYT...

CYAD - Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC

MONT-SAINT-GUIBERT, Belgium, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today that the Compan...

CYAD - Celyad Oncology to Participate in a Fireside Chat at the 7th Annual Jefferies Cell Therapy Summit

MONT-SAINT-GUIBERT, Belgium, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Filippo Pe...
CYAD - Celyad Oncology to Host Virtual Research & Development Webinar on September 29

MONT-SAINT-GUIBERT, Belgium, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it will host a ...

CYAD - Celyad Oncology inks $25M stock sales deal

Celyad Oncology (NASDAQ: CYAD ) enters into an agreement  with Jefferies for the at-the-market sale of up to $25M of new American Depositary Shares (ADSs), assuming sale of 2,522,704 ADSs at $9.91/ADS, for a period of 36 months. More news on: Celyad Oncology SA, Healthcare stocks n...

CYAD - Celyad Oncology Establishes At-the-Market Facility

MONT-SAINT-GUIBERT, Belgium, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has ent...
CYAD - Celyad Oncology Announces September 2020 Conference Schedule

MONT-SAINT-GUIBERT, Belgium, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company...

CYAD - Celyad Oncology's (CYAD) CEO Filippo Petti on First Half 2020 Results - Earnings Call Transcript

Celyad Oncology SA (CYAD) First Half 2020 Earnings Conference Call August 07, 2020 8:00 AM ET Company Participants Filippo Petti – Chief Executive Officer David Gilham – Chief Scientific Officer Conference Call Participants Raju Prasad – William Blair J...

CYAD - Celyad Oncology reports 1H results

Celyad Oncology (NASDAQ: CYAD ) : 1H Net loss of €16.6M. More news on: Celyad Oncology SA, Earnings news and commentary, Healthcare stocks news, , Read more ...

Previous 10 Next 10